Stem cells for relevant efficient extended and normalized toxicology (SCR&Tox)
Owner/Developer: European Commission and Cosmetics Europe
In the development of products for use by humans it is vital to identify compounds with toxic properties at an early stage of their development, to avoid spending time and resource on unsuitable and potentially unsafe candidate products. Human pluripotent stem cell lines offer a unique opportunity to develop a wide variety of human cell-based test systems because they may be expanded indefinitely and triggered to differentiate into any cell type. SCR&Tox aims at making use of these two attributes to provide in vitro assays for predicting toxicity of pharmaceutical compounds and cosmetic ingredients. The consortium has been designed to address all issues related with biological and technological resources to meet that goal.
|Channel:||Face-to-face - Website - Social media - Printed|
|Audience:||Scientists - Regulators - Industry - Researchers|
|User access:||Open access|
|Updating frequency:||Last updated: 01 November 2015|
|Purpose:||Regulatory testing - Toxicological and safety evaluation - Method development - Documentation and information|
|Technology/Tools:||Alternative test methods (in vitro) - Stem cells|
Did you find what you were looking for?Yes, I found it! No, I did not!
Thanks for your feedback! Please note that we cannot respond unless you supply your email address.
What are you looking for?
Please give us your feedback so we can improve the information on the page. Thank you in advance for your help. Please add your email address if you would like a reply.Please contact us by email if you have any questions.